Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5219555 | 0.88 | ESR1 (0.78) | ESR1MAPTKDM4ETP53CYP1A2 | |
| SCHEMBL5216555 | 0.88 | ESR1 (0.78) | ESR1MAPTKDM4ETP53CYP1A2 | |
| SCHEMBL5222121 | 0.83 | ESR1 (0.71) | ESR1MAPTKDM4ETP53CYP1A2 | |
| SCHEMBL5214596 | 0.82 | ESR1 (0.69) | ESR1MAPTKDM4ETP53CYP1A2 | |
| SCHEMBL5218664 | 0.82 | ESR1 (0.69) | ESR1MAPTKDM4ETP53CYP1A2 | |
| SCHEMBL5221678 | 0.82 | ESR1 (0.69) | ESR1MAPTKDM4ETP53CYP1A2 | |
| SCHEMBL5217314 | 0.81 | ESR1 (0.68) | ESR1MAPTKDM4ETP53CYP1A2 | |
| SCHEMBL5216546 | 0.80 | ESR1 (0.66) | ESR1MAPTKDM4ETP53CYP1A2 | |
| SCHEMBL5214127 | 0.80 | ESR1 (0.66) | ESR1MAPTKDM4ETP53CYP1A2 | |
| SCHEMBL5216299 | 0.79 | ESR1 (0.64) | ESR1MAPTKDM4ETP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119278262-A | Method of | 乔赛诺迪公司 | 2025-01-07 | — | — | CN | claimed |
| CN-118477176-A | Estrogen analogue, estrogen receptor activator and application thereof | 广州国家实验室 | 2024-08-13 | — | — | CN | claimed |
| US-20240263135-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | claimed |
| CN-114342873-B | Method for preparing ZZ genotype Chinese softshell turtle pseudo-female individual by using non-hormone compound | 浙江万里学院 | 2022-11-25 | — | — | CN | claimed |
| CN-114342873-A | Method for preparing ZZ genotype Chinese softshell turtle pseudo-female individual by using non-hormone compound | 浙江万里学院 | 2022-04-15 | — | — | CN | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| US-20210393695-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2021-12-23 | — | — | US | claimed |
| EP-3495487-B1 | PROMOTER WITH A REGION RICH IN CYTOSINE-GUANINE DINUCLEOTIDES, VECTORS, CELLULAR LINES, METHOD FOR PRODUCING RECOMBINANT PROTEIN | UNIV CHILE (CL) | 2026-04-29 | — | — | EP | disclosed |
| US-12419870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250215396-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12281329-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119278262-A | Method of | 乔赛诺迪公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
| EP-1812404-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2007-08-01 | — | — | EP | disclosed |
| US-20070135407-A1 | Serm reduction of lipid profiles | GTX, INC | 2007-06-14 | — | — | US | disclosed |
| WO-2006040351-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2006-04-20 | — | — | WO | disclosed |
| EP-1647549-A1 | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents | LABORATOIRE THERAMEX (MC) | 2006-04-19 | — | — | EP | disclosed |
| US-20050202432-A1 | Estrogen receptor alpha regulated gene expression, related assays and therapeutics | WYETH | 2005-09-15 | — | — | US | disclosed |
| WO-2003087336-A2 | ESTROGEN RECEPTOR ALPHA REGULATED GENE EXPRESSION, RELATED ASSAYS AND THERAPEUTICS | WYETH (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885MAPT 869/4885KDM4E 1462/4885 |
| US-20070135407-A1 | Serm reduction of lipid profiles | SHBG, NR5A1, APOB | ESR1 153/4885MAPT 2449/4885KDM4E 3538/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ESR1 4646/4885MAPT 2171/4885KDM4E 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.